Literature DB >> 1412524

Pentamidine isethionate is negative in tests for microbial mutagenicity and chromosomal breakage in vitro.

T H Connor1, Z Trizna.   

Abstract

Pentamidine isethionate, a drug used for the treatment of Pneumocystis carinii pneumonia in AIDS patients, was assayed for mutagenicity in five strains of Salmonella typhimurium and for clastogenicity and mutagen-induced chromosomal breakage in five human lymphoblastoid cell lines. The mutagenicity assay employed both repair-deficient and repair-positive strains without and with the addition of rat liver S-9. There was no indication of a mutagenic response in any of the strains of Salmonella. Chromosomal breakage was measured in lymphoblastoid cell lines, both in the absence and presence of bleomycin. Following 2, 5 and 24 h of treatment, pentamidine alone did not induce clastogenicity, nor was there an increase in chromosomal breakage when the cell lines were treated with bleomycin simultaneously with, or 22 h prior to, the addition of pentamidine. From these data it can be concluded that pentamidine is not mutagenic or clastogenic in the two assays employed in this study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412524     DOI: 10.1016/0378-4274(92)90108-v

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  3 in total

1.  Antimutagenic and antioxidant activity of novel 4-substituted phenyl-2,2'-bichalcophenes and aza-analogs.

Authors:  Wael M El-Sayed; Warda A Hussin
Journal:  Drug Des Devel Ther       Date:  2013-02-04       Impact factor: 4.162

2.  Evaluation of the biological activity of novel monocationic fluoroaryl-2,2'-bichalcophenes and their analogues.

Authors:  Warda A Hussin; Mohamed A Ismail; Abdullah M Alzahrani; Wael M El-Sayed
Journal:  Drug Des Devel Ther       Date:  2014-07-17       Impact factor: 4.162

3.  HIV chromatin is a preferred target for drugs that bind in the DNA minor groove.

Authors:  Clayton K Collings; Donald W Little; Samuel J Schafer; John N Anderson
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.